Estrella Immunopharma Inc (ESLA)

$1.54 -0.05 (-3.14%)
Market Cap 60.05M
Revenue (ttm) 0.00
Net Income (ttm) -7.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 15,800
Avg Vol 300,118
Day's Range N/A - N/A
Shares Out 37.77M
Stochastic %K 25%
Beta 0.53
Analysts Strong Sell
Price Target $16.00

Company Profile

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 318 9098
Address:
5858 Horton Street, Suite 370, EmeryVille, United States
NylonNod
NylonNod Dec. 27 at 12:47 PM
$ESLA Confidence will depend on whether guidance becomes dependable; organic growth must prove sustainable without incentives — consistent delivery could invite longer‑term shareholders. Until validation appears, volatility remains the default.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 27 at 3:40 AM
$ESLA
0 · Reply
BackwardationV2
BackwardationV2 Dec. 25 at 1:16 PM
$ESLA The strategic path forward will be judged on practical milestones, not narrative strength. The market is increasingly intolerant of delays that stretch credibility. If milestones arrive on time, perception can shift faster than fundamentals. Investors will likely wait for pattern recognition before re‑committing capital.
0 · Reply
JohnTrack
JohnTrack Dec. 22 at 4:52 PM
$ESLA update just released... https://www.rapidticker.com/news/esla-sec-filing-072f23
0 · Reply
Colonia
Colonia Dec. 19 at 3:25 PM
$ESLA I see a large buy order pending. Extension on phase II? $TSLA holding for 100% $BTC watching for a potential increase in position $IRBT people still buying this? $SAVA ouch!
0 · Reply
topstockalerts
topstockalerts Dec. 4 at 2:58 PM
Estrella Immunopharma said its CD19-targeted cancer therapy received clearance to advance into Phase II testing. An independent safety board recommended moving its STARLIGHT-1 trial into an expansion phase after a favorable safety review of EB103 for relapsed or refractory B-cell non-Hodgkin lymphoma. The Phase I dose-escalation stage showed no treatment-related serious adverse events in nine patients, many considered high risk, and the high-dose cohort achieved a 100% complete response rate at Month 1. Estrella called this a major milestone, noting EB103’s strong safety profile and full responses suggest it may overcome toxicity challenges that have historically limited CD19-targeted CAR-T therapies. The expansion phase will further evaluate safety and early efficacy at the recommended Phase II dose. $ESLA
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 1:15 PM
$ESLA there it goes … 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰
0 · Reply
www_larval_com
www_larval_com Nov. 17 at 8:53 PM
$CYPH -7%[-12%] $MIST 6%[17%] $ESLA -4%[-17%] $ONEG 4%[-58%] $VENU -4%[-20%] most notable movement into the final minutes of trading.
0 · Reply
www_larval_com
www_larval_com Nov. 12 at 8:52 PM
$CYPH 7%[387%] $ESLA 4%[-16%] $CMCT 4%[93%] $FTCI 3%[47%] $WLDS 3%[39%] most notable movement into the final minutes of trading.
0 · Reply
WendyMorell1077
WendyMorell1077 Nov. 6 at 4:04 PM
$ESLA attracts attention as electric and automation themes rise. AITX demonstrates sector leadership through next-generation perimeter monitoring technologies.
0 · Reply
Latest News on ESLA
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Dec 4, 2025, 8:00 AM EST - 23 days ago

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Nov 3, 2025, 8:00 AM EST - 7 weeks ago

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Oct 6, 2025, 8:00 AM EDT - 2 months ago

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Jun 5, 2025, 8:00 AM EDT - 7 months ago

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Jun 3, 2025, 8:00 AM EDT - 7 months ago

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

May 29, 2025, 8:01 AM EDT - 7 months ago

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Mar 5, 2025, 8:00 AM EST - 10 months ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Feb 21, 2025, 8:30 AM EST - 11 months ago

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Feb 19, 2025, 4:46 PM EST - 11 months ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Sep 27, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Aug 14, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Sep 29, 2023, 10:34 AM EDT - 2 years ago

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Estrella Immunopharma Nears Completion Of SPAC Listing

Sep 19, 2023, 1:30 AM EDT - 2 years ago

Estrella Immunopharma Nears Completion Of SPAC Listing

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Sep 18, 2023, 5:00 PM EDT - 2 years ago

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

Oct 3, 2022, 7:27 AM EDT - 3 years ago

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

NylonNod
NylonNod Dec. 27 at 12:47 PM
$ESLA Confidence will depend on whether guidance becomes dependable; organic growth must prove sustainable without incentives — consistent delivery could invite longer‑term shareholders. Until validation appears, volatility remains the default.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 27 at 3:40 AM
$ESLA
0 · Reply
BackwardationV2
BackwardationV2 Dec. 25 at 1:16 PM
$ESLA The strategic path forward will be judged on practical milestones, not narrative strength. The market is increasingly intolerant of delays that stretch credibility. If milestones arrive on time, perception can shift faster than fundamentals. Investors will likely wait for pattern recognition before re‑committing capital.
0 · Reply
JohnTrack
JohnTrack Dec. 22 at 4:52 PM
$ESLA update just released... https://www.rapidticker.com/news/esla-sec-filing-072f23
0 · Reply
Colonia
Colonia Dec. 19 at 3:25 PM
$ESLA I see a large buy order pending. Extension on phase II? $TSLA holding for 100% $BTC watching for a potential increase in position $IRBT people still buying this? $SAVA ouch!
0 · Reply
topstockalerts
topstockalerts Dec. 4 at 2:58 PM
Estrella Immunopharma said its CD19-targeted cancer therapy received clearance to advance into Phase II testing. An independent safety board recommended moving its STARLIGHT-1 trial into an expansion phase after a favorable safety review of EB103 for relapsed or refractory B-cell non-Hodgkin lymphoma. The Phase I dose-escalation stage showed no treatment-related serious adverse events in nine patients, many considered high risk, and the high-dose cohort achieved a 100% complete response rate at Month 1. Estrella called this a major milestone, noting EB103’s strong safety profile and full responses suggest it may overcome toxicity challenges that have historically limited CD19-targeted CAR-T therapies. The expansion phase will further evaluate safety and early efficacy at the recommended Phase II dose. $ESLA
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 1:15 PM
$ESLA there it goes … 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰
0 · Reply
www_larval_com
www_larval_com Nov. 17 at 8:53 PM
$CYPH -7%[-12%] $MIST 6%[17%] $ESLA -4%[-17%] $ONEG 4%[-58%] $VENU -4%[-20%] most notable movement into the final minutes of trading.
0 · Reply
www_larval_com
www_larval_com Nov. 12 at 8:52 PM
$CYPH 7%[387%] $ESLA 4%[-16%] $CMCT 4%[93%] $FTCI 3%[47%] $WLDS 3%[39%] most notable movement into the final minutes of trading.
0 · Reply
WendyMorell1077
WendyMorell1077 Nov. 6 at 4:04 PM
$ESLA attracts attention as electric and automation themes rise. AITX demonstrates sector leadership through next-generation perimeter monitoring technologies.
0 · Reply
Pb1782
Pb1782 Nov. 4 at 2:51 PM
$ESLA
0 · Reply
StockScanners
StockScanners Nov. 4 at 2:05 AM
$ESLA keep watch if this holds above 2.77
0 · Reply
stockwitsuser2449
stockwitsuser2449 Nov. 3 at 11:07 PM
$ESLA
0 · Reply
Pb1782
Pb1782 Nov. 3 at 9:16 PM
$ESLA
0 · Reply
topstockalerts
topstockalerts Nov. 3 at 8:51 PM
$ESLA Strong action today..
0 · Reply
AlGo88
AlGo88 Nov. 3 at 7:44 PM
$ESLA nice
0 · Reply
mibulldog
mibulldog Nov. 3 at 6:54 PM
$ESLA Up 220% in last 3 months, positive results for clinical trial of EB103. Only 314 watching?? Need to get more eyes on this.
0 · Reply
_luke637
_luke637 Nov. 3 at 5:55 PM
$ESLA
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 4:24 PM
D. Boral Capital has adjusted their stance on Estrella Immunopharma ( $ESLA ), setting the rating to Buy with a target price of 16.
0 · Reply
hsfjhv
hsfjhv Nov. 3 at 3:01 PM
$ESLA where is everyone? 100% complete response (CR) rate at Month 1 in all evaluable patients treated
0 · Reply
www_larval_com
www_larval_com Oct. 28 at 7:58 PM
$VRA 4%[20%] $DVLT 4%[0%] $FUSE 4%[21%] $ESLA 3%[10%] $CLIK 3%[-28%] most notable movement into the final minutes of trading.
0 · Reply
Stocksiren
Stocksiren Oct. 24 at 3:34 PM
$ESLA
0 · Reply